NVS vs RPRX
Novartis AG vs Royalty Pharma plc — AI-powered side-by-side comparison
VS
RPRX
Royalty Pharma plc
56
Watch
| Metric | NVS | RPRX |
|---|
| AI Score |
75
|
56
|
| Price |
$154.64
|
$57.79
|
| P/E Ratio |
23.55×
|
23.98×
|
| ROE |
30.5%
|
11.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
89.4%
|
| Debt / Equity |
1.18×
|
1.31×
|
| Dividend Yield |
2.9%
|
1.6%
|
| RSI (14) |
57.7
|
49.6
|
| Beta |
0.462
|
0.425
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus RPRX.
NVS leads by 19 points.
NVS scores 75/100 (Buy) versus RPRX at 56/100 (Watch).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
RPRX Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical